Biology:Active hexose correlated compound

From HandWiki
Active Hexose Correlated Compound is a chemical isolated from the Shiitake mushroom.

Active Hexose Correlated Compound (AHCC) is an alpha-glucan rich nutritional supplement produced from the mycelia of shiitake (Lentinula edodes) of the basidiomycete family of mushrooms. The compound is a subject of research as a potential anti-cancer agent but has not been conclusively found to treat cancer or any other disease, and there are conflict of interest concerns about the published research.[1][2] AHCC is a popular alternative medicine in Japan.[3]

Chemical composition

Polysaccharides comprise 40% of the composition of AHCC[citation needed]. These include beta-glucan (β-glucan) and acetylated α-glucan. Acetylated α-glucan, produced by culturing the mushroom mycelia, is unique to AHCC[citation needed]. Glucans are polysaccharides and these polysaccharides are known to have immune stimulating effects.[4]

As a supplemental alternative medicine

AHCC is widely used in Japan and China. It is available to the general public in Japan and China without a prescription and many people use it for general health maintenance and treatment of acute infections. Its legal status is that of a "functional food".

In Japan, AHCC is the 2nd most popular complementary and alternative medicine used by cancer patients. Agaricus blazei supplements are the most popular, outpacing AHCC use by a factor of 7:1.[3]

Research

Nearly all of the research into AHCC has been funded by the manufacturer, which complicates the discussion of currently available results – independent research is needed to verify them.[2] The mechanism of action of AHCC is poorly understood and there is little known about its safety.[2] (As of 2011) clinical research into AHCC has been of poor quality: there are no large-scale studies or randomized controlled trials.[2]

Laboratory research suggests AHCC may have immunostimulatory effects.[2]

AHCC has been proposed as a treatment for cancer, but research into its effectiveness has produced only uncertain and inconclusive evidence.[1] Detailed research is needed into the pharmacology of AHCC before any recommendation of its use as an adjuvant therapy can be made.[2]

See also

References

  1. 1.0 1.1 "AHCC". WebMD. http://www.webmd.com/vitamins-supplements/ingredientmono-1110-ahcc.aspx?activeingredientid=1110&activeingredientname=ahcc. Retrieved 23 September 2018. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 "An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient". JPEN J Parenter Enteral Nutr 35 (4): 449–58. 2011. doi:10.1177/0148607110380684. PMID 21628606. "It is important to note that the vast majority of the published research on AHCC has been supported by the manufacturer.". 
  3. 3.0 3.1 "Nationwide survey on complementary and alternative medicine in cancer patients in Japan". Journal of Clinical Oncology 23 (12): 2645–54. April 2005. doi:10.1200/JCO.2005.04.126. PMID 15728227. 
  4. Fujii H, Nakagawa T: Novel substance having physiological activity, process for producing the same, and use, U.S. Patent Application Publication, Mar 6, 2003.